Totect is available at two price options to help increase immediate access to Totect for oncology practices, hospitals, infusion centers and clinics. For general information and full prescribing information, including clinical trial information, safety, dosing, drug interactions and contraindications, please visit www.totect.com or call (866) 914-2922. To order Totect, please call (800) 746-6273.
Contraindications: None known Warnings: Pregnancy Category D Precautions: Totect is a cytotoxic drug. When administered to patients receiving anthracycline containing cytotoxic therapy, additive cytotoxicity may occur. Treatment with Totect is associated with leukopenia, neutropenia, and thrombocytopenia. Hematological monitoring should be performed. Reversible elevations of liver enzymes may occur with dexrazoxane. Patients with Moderate or Severe Renal Insufficiency: Greater exposure to dexrazoxane may in occur in patients with compromised renal function. The Totect dose should be reduced by 50% in patients with creatinine clearance values <40mL/min. Dimethylsulfoxide (DMSO) should not be used in patients who are receiving dexrazoxane to treat anthracycline-induced extravasation. Laboratory Tests: Blood counts and liver enzymes should be monitored. Adverse Reactions: Dexrazoxane has been studied previously as a cytotoxic agent. Adverse reactions of nausea/vomiting, diarrhea, stomatitis, bone marrow suppression (neutropenia, thrombocytopenia), altered liver function (increased AST/ALT
|SOURCE TopoTarget USA, Inc.|
Copyright©2009 PR Newswire.
All rights reserved